Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors
Sprecher E, Sarkar S, Kleinstein S, Narayan M, Winer E, Tuck D, Lezon-Geyda K, Krop I, Harris L. Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors. 2011, 446-450. DOI: 10.1145/2147805.2147867.Peer-Reviewed Original ResearchEarly-stage HER2Breast cancer patientsBreast tumorsTrastuzumab treatmentCancer patientsCell linesHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Breast cancer settingGrowth factor receptor 2Resistant breast tumorsTrastuzumab-resistant HER2Breast cancer cell linesClinical treatment decisionsFactor receptor 2Trastuzumab exposureCancer cell linesGene expression signaturesResponsive patientsTrastuzumab resistanceSingle doseTargeted therapyBreast cancerCancer settingTreatment decisionsCell subset prediction for blood genomic studies
Bolen CR, Uduman M, Kleinstein SH. Cell subset prediction for blood genomic studies. BMC Bioinformatics 2011, 12: 258. PMID: 21702940, PMCID: PMC3213685, DOI: 10.1186/1471-2105-12-258.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsTotal peripheral blood mononuclear cellsGene signatureSubset-specific genesBlood mononuclear cellsPatient blood samplesPersonalized treatment decisionsSpecific cell subsetsHCV patientsPBMC subsetsNK cellsStandard therapyCell subsetsMononuclear cellsT cellsTreatment decisionsTherapy responseBlood samplesB cellsMyeloid cellsCellular sourceTranscriptional profilingDisease mechanismsGene expression profilesCells